Updated the QVAR Redihaler® effective coverage Oct. 1, 2023 as noted in footnote 2
View alternative covered options
Drug manufacturer GlaxoSmithKline (GSK) recently notified the U.S. Food and Drug Administration (FDA) that they would be discontinuing 2 of their brand products, Flovent Diskus and Flovent HFA. According to the announcement, the last date these products will be available for ordering is Dec. 31, 2023.
Preferred covered alternatives
We have identified preferred covered alternatives to help ensure your UnitedHealthcare patients continue to have access to a covered inhaled corticosteroid to treat their respiratory conditions.
Refer to the table below to determine if any of the preferred covered alternatives are suitable options. You can also use PreCheck MyScript via most “electronic medical records’ real-time benefit check functionality” or the UnitedHealthcare Provider Portal to view other covered alternatives.
Preferred covered inhaled corticosteroids
UnitedHealthcare commercial plans
Arnuity Ellipta and QVAR Redihaler®1
Individual Exchange plans, also referred to as UnitedHealthcare Individual and Family ACA Marketplace plans
Individual UnitedHealthcare® Medicare Advantage and stand-alone Part D plans
For plans that currently cover Flovent: Arnuity Ellipta and QVAR Redihaler®2
For plans that currently do not cover Flovent: Pulmicort Flexhaler, ArmonAir® Digihaler®
Send us a message or chat with a live advocate 7 a.m.–7 p.m. CT from the Contact Us page.
1QVAR Redihaler® will be brought into coverage Jan. 1, 2024, for UnitedHealthcare commercial plans and the Flovent products will be excluded.
2 QVAR Redihaler® will be brought into coverage Oct. 1, 2023, for Individual UnitedHealthcare® Medicare Advantage and standalone Part D plans that currently cover Flovent and Flovent products will be covered until no longer commercially available.